PVR and neoplasm: ZGGS15, a BsAb that blocks both LAG-3 and TIGIT, can potently inhibit LAG-3 and TIGIT receptors on immune cells by attaching to their specific binding ligands, MHC-II and PVR (CD155), on tumor cells.